Nuvig Therapeutics

Rebalancing immune function for autoimmune diseases

Palo Alto, United States · Founded 2022 · $208.0M raised

Employees
11–50
Founded
2022
Business Model
B2B
Total Funding
$208.0M
Last Round
$47.0M Series ADec 2024
Rounds
2

About

Nuvig Therapeutics is a clinical-stage biotechnology company headquartered in Palo Alto, California, developing next-generation immune modulators that rebalance immune function for patients with chronic inflammatory and autoimmune diseases. Its core technology harnesses an endogenous regulatory mechanism to resolve autoimmune dysregulation without broadly suppressing the immune system. The company's lead candidate, NVG-2089, is in Phase 2 development for chronic inflammatory demyelinating polyneuropathy (CIDP), backed by a $161 million Series B financing.

Summary

Nuvig Therapeutics is a Biotech company based in Palo Alto, United States, founded in 2022. It has raised $208.0M in total across 2 rounds, most recently a $47.0M Series A round in Dec 2024.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series BSeries BDec 2024
$161.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nuvig Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/nuvig-therapeutics"><img src="https://indexed.vc/api/badge/company/nuvig-therapeutics" alt="Nuvig Therapeutics on Indexed.vc" width="260" height="76" /></a>